Aurora Innovation, Inc 10-Q for FY2021 Q2
Aurora Innovation, Inc. (AUR)
About this 10-Q
Aurora Innovation, Inc filed this 10-Q on August 11, 2021, covering the quarter ended June 30, 2021 (FY2021 Q2).
Headline figures
Quarter ended June 30, 2021, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $3.61M
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) | |
(Address of principal executive offices) |
(Zip Code) | |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-eighth of one redeemable warrant |
||||
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company | ||||||
Page No. |
||||||
Item 1. |
3 |
|||||
3 |
||||||
4 |
||||||
5 |
||||||
6 |
||||||
7 |
||||||
Item 2. |
20 |
|||||
Item 3. |
25 |
|||||
Item 4. |
25 |
|||||
Item 1. |
26 |
|||||
Item 1A. |
26 |
|||||
Item 2. |
26 |
|||||
Item 3. |
27 |
|||||
Item 4. |
27 |
|||||
Item 5. |
27 |
|||||
Item 6. |
27 |
|||||
29 |
||||||
June 30, 2021 |
December 31, 2020 |
|||||||
Assets: |
(unaudited) | |||||||
| Current assets: |
||||||||
| Cash |
$ | $ | — | |||||
| Prepaid expenses |
||||||||
| |
|
|
|
|||||
| Total current assets |
||||||||
| Deferred offering costs associated with proposed public offering |
— | |||||||
| Investment held in Trust Account |
— | |||||||
| |
|
|
|
|||||
| Total Assets |
$ |
$ |
||||||
| |
|
|
|
|||||
| Liabilities and Shareholders’ Equity: |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | $ | ||||||
| Accrued expenses |
||||||||
| Due to related party |
— | |||||||
| |
|
|
|
|||||
| Total current liabilities |
||||||||
| Deferred legal fees |
— | |||||||
| Deferred underwriting commissions |
— | |||||||
| Derivative warrant liabilities |
— | |||||||
| |
|
|
|
|||||
| Total liabilities |
||||||||
| Commitments and Contingencies |
||||||||
| Class A ordinary shares, $ |
— | |||||||
| Shareholders’ Equity: |
||||||||
| Preference shares, $ |
— | |||||||
| Class A ordinary shares, $ and 0 shares subject to possible redemption) at June 30, 2021 and December 31, 2020, respectively |
— | |||||||
| Class B ordinary shares, $ |
||||||||
| Additional paid-in capital |
||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Total shareholders’ equity |
||||||||
| |
|
|
|
|||||
| Total Liabilities and Shareholders’ Equity |
$ |
$ |
||||||
| |
|
|
|
|||||
For the three months ended June 30, 2021 |
For the six months ended June 30, 2021 |
|||||||
| General and administrative expenses |
$ | $ | ||||||
| |
|
|
|
|||||
| Loss from operations |
( |
) | ( |
) | ||||
| Other income (expense) |
||||||||
| Change in fair value of derivative warrant liabilities |
( |
) | ( |
) | ||||
| Financing costs - derivative warrant liabilities |
( |
) | ||||||
| Unrealized gain on investments held in Trust Account |
||||||||
| |
|
|
|
|||||
| Total other income (expense) |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Net loss |
$ | ( |
) | $ | ( |
) | ||
| |
|
|
|
|||||
| Basic and diluted weighted average shares outstanding of Class A ordinary shares |
||||||||
| |
|
|
|
|||||
| Basic and diluted net loss per ordinary share |
$ | $ | ||||||
| |
|
|
|
|||||
| Basic and diluted weighted average shares outstanding of Class B ordinary shares |
||||||||
| |
|
|
|
|||||
| Basic and diluted net loss per ordinary share |
$ | ( |
) | $ | ( |
) | ||
| |
|
|
|
|||||
Ordinary Shares |
Additional Paid-in Capital |
Accumulated Deficit |
Total Shareholders’ Equity |
|||||||||||||||||||||||||
Class A |
Class B |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Balance - December 31, 2020 |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
Sale of units in initial public offering, less allocation to derivative warrant liabilities |
— | — | — | |||||||||||||||||||||||||
Offering costs |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Excess of cash receipts over the fair value of the private warrants sold to Sponsor |
— | — | — | — | — | |||||||||||||||||||||||
Shares subject to possible redemption |
( |
) | ( |
) | — | — | ( |
) | — | ( |
) | |||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
Balance - March 31, 2021 (unaudited) |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
Shares subject to possible redemption |
— | — | — | |||||||||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
Balance - June 30, 2021 (unaudited) |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
| Cash Flows from Operating Activities: |
||||
| Net loss |
$ | ( |
) | |
| Change in fair value of derivative warrant liabilities |
||||
| Financing costs - derivative warrant liabilities |
||||
| Unrealized gain on investments held in Trust Account |
( |
) | ||
| Changes in operating assets and liabilities: |
||||
| Prepaid expenses |
( |
) | ||
| Accounts payable |
||||
| Accrued expenses |
||||
| Due to related party |
||||
| |
|
|||
| Net cash used in operating activities |
( |
) | ||
| |
|
|||
| Cash Flows from Investing Activities: |
||||
| Cash deposited in Trust Account |
( |
) | ||
| |
|
|||
| Net cash used in investing activities |
( |
) | ||
| |
|
|||
| Cash Flows from Financing Activities: |
||||
| Repayment of note payable to related party |
( |
) | ||
| Proceeds received from initial public offering, gross |
||||
| Proceeds received from private placement |
||||
| Offering costs paid |
( |
) | ||
| |
|
|||
| Net cash provided by financing activities |
||||
| |
|
|||
| Net increase in cash |
||||
| Cash - beginning of the period |
||||
| |
|
|||
| Cash - end of the period |
$ |
|||
| |
|
|||
| Supplemental disclosure of noncash investing and financing activities: |
||||
| Offering costs included in accrued expenses |
$ | |||
| Offering costs paid by related party under promissory note |
$ | |||
| Deferred legal fees |
$ | |||
| Deferred underwriting commissions |
$ | |||
| Initial value of Class A ordinary shares subject to possible redemption |
$ | |||
| Change in value of Class A ordinary shares subject to possible redemption |
$ | ( |
) | |
| • | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; |
| • | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
| • | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
For the three months ended June 30, 2021 |
For the six months ended June 30, 2021 |
|||||||
Class A ordinary shares |
||||||||
Numerator: Earnings allocable to Class A ordinary shares |
||||||||
Unrealized gain on investments held in Trust Account |
$ |
$ |
||||||
Less: Company’s portion available to be withdrawn to pay taxes |
$ |
( |
) |
$ |
( |
) | ||
Net income attributable to Class A ordinary shares |
$ |
— |
$ |
— |
||||
Denominator: Weighted average Class A ordinary shares |
||||||||
Basic and diluted weighted average shares outstanding |
||||||||
Basic and diluted net income per share |
$ |
— |
$ |
— |
||||
Class B ordinary shares |
||||||||
Numerator: Net Loss minus Net Earnings allocable to Class A ordinary shares |
||||||||
Net loss |
$ |
( |
) |
$ |
( |
) | ||
Net income allocable to Class A ordinary shares |
— |
— |
||||||
Net loss allocable to Class B ordinary shares |
$ |
( |
) |
$ |
( |
) | ||
Denominator: weighted average Class B ordinary shares |
||||||||
Basic and diluted weighted average shares outstanding, Class B ordinary shares |
||||||||
Basic and diluted net loss per share, Class B ordinary shares |
$ |
( |
) |
$ |
( |
) | ||
| • | in whole and not in part; |
| • | at a price of $ W arrant; |
| • | upon not less than W arrant holder; and |
| • | if, and only if, the last reported sale price of Class A ordinary shares for any W arrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted). |
| • | in whole and not in part; |
| • | at $ W arrant upon a minimum of W arrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; |
| • | if, and only if, the Reference Value equals or exceeds $ |
| • | if the Reference Value is less than $ |
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
| Assets: |
||||||||||||
| Investments held in Trust Account – U.S. Treasury Securities Money Market Fund |
$ | $ | — | $ | — | |||||||
| Liabilities: |
||||||||||||
| Derivative warrant liabilities – public warrants |
$ | $ | — | $ | — | |||||||
| Derivative warrant liabilities – private warrants |
$ | — | $ | — | $ | |||||||
As of June 30, 2021 |
||||
| Stock price |
$ | |||
| Volatility |
% | |||
| Expected life of the options to convert |
||||
| Risk-free rate |
% | |||
| Dividend yield |
||||
Public Warrants |
Private Warrants |
Total |
||||||||||
| Derivative warrant liabilities at December 31, 2020 |
$ | $ | $ | |||||||||
| Issuance of derivative warrant liabilities |
||||||||||||
| Transfer of Public Warrants to Level 1 |
( |
) | — | ( |
) | |||||||
| Change in fair value of derivative warrant liabilities |
||||||||||||
| |
|
|
|
|
|
|||||||
| |
|
|
|
|
|
|||||||
| Derivative warrant liabilities at June 30, 2021 |
$ | $ | $ | |||||||||
| |
|
|
|
|
|
|||||||
| • | at the closing of the transactions contemplated by the Merger Agreement (the “Closing”), upon the terms and subject to the conditions of the Merger Agreement, in accordance with the General Corporation Law of the State of Delaware, as amended (the “DGCL”), Merger Sub will merge with and into Aurora, the separate corporate existence of Merger Sub will cease and Aurora will be the surviving corporation and a wholly owned subsidiary of the Company (the “Merger”); |
| • | upon the effective time of the Domestication (defined below), the Company will immediately be renamed “Aurora Innovation, Inc.” (after the Domestication, the Company is referred to as “Aurora Innovation”); |
| • | as a result of the Merger, among other things, all outstanding shares of Aurora capital stock will be cancelled in exchange for the right to receive shares of Aurora Innovation Class A common stock (at a deemed value of $ a pre-transaction equity value of Aurora of $ |
| • | as a result of the Merger, all outstanding Aurora equity awards outstanding as of immediately prior to the effective time of the Merger that will be converted into awards based on Aurora Innovation Class A common stock. |
| • | at the closing of the transactions contemplated by the Merger Agreement (the “Closing”), upon the terms and subject to the conditions of the Merger Agreement, in accordance with the General Corporation Law of the State of Delaware, as amended (the “DGCL”), Merger Sub will merge with and into Aurora, the separate corporate existence of Merger Sub will cease and Aurora will be the surviving corporation and our wholly owned subsidiary (the “Merger”); |
| • | upon the effective time of the Domestication (defined below), we will immediately be renamed “Aurora Innovation, Inc.” (after the Domestication, the Company is referred to as “Aurora Innovation”); |
| • | as a result of the Merger, among other things, all outstanding shares of Aurora capital stock will be cancelled in exchange for the right to receive shares of Aurora Innovation Class A common stock (at a deemed value of $10.00 per share) and shares of Aurora Innovation Class B common stock (at a deemed value of $10.00 per share) representing a pre-transaction equity value of Aurora of $11.0 billion; the Aurora Innovation Class B common stock will have the same economic terms as the Aurora Innovation Class A common stock, but the Aurora Innovation Class B common stock will carry ten votes per share while the Aurora Innovation Class A common stock will carry one vote per share; and |
| • | as a result of the Merger, all outstanding Aurora equity awards outstanding as of immediately prior to the effective time of the Merger that will be converted into awards based on Aurora Innovation Class A common stock. |
| • | we have implemented procedures intended to ensure that we identify and apply the applicable accounting guidance to all complex transactions; and |
| • | we are establishing additional monitoring and oversight controls designed to ensure the accuracy and completeness of our consolidated financial statements and related disclosures. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document* | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document* | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document* | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)* | |
| * | Filed herewith. |
| ** | Furnished. |
REINVEST TECHNOLOGY PARTNERS Y | ||
| By: | /s/ Michael Thompson | |
| Name: | Michael Thompson | |
| Title: | Chief Executive Officer and Chief Financial Officer | |
EXHIBIT 31.1
CERTIFICATION
PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Thompson, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the period three and six months ended June 30, 2021 of Reinvent Technology Partners Y; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | [Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942]; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting. |
| Date: August 11, 2021 | By: | /s/ Michael Thompson | ||||
| Michael Thompson | ||||||
| Chief Executive Officer, Chief Financial Officer (Principal Executive & Financial Officer) |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Reinvent Technology Partners Y (the “Company”) on Form 10-Q for the three and six months ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Thompson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: August 11, 2021
| /s/ Michael Thompson | ||
| Name: | Michael Thompson | |
| Title: | Chief Executive Officer, Chief Financial Officer (Principal Executive & Financial Officer) | |